Literature DB >> 8106354

Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.

R J Lee1, P S Low.   

Abstract

Folic acid was covalently conjugated to 66-nm liposomes via spacers of various lengths in an attempt to target the liposomes to KB cells expressing folate receptors. Spacers of short and intermediate lengths were unable to mediate association of folate-conjugated liposomes with receptor-bearing cells, however, use of a 250 A polyethyleneglycol spacer (PEG, M(r) approximately 3350) permitted avid uptake of the liposomes at approximately 2.5 x 10(5) sites/cell. The binding of folate-PEG liposomes to KB cells could be competitively inhibited by excess free folate or by antiserum against the folate receptor, demonstrating the interaction is mediated by the cell surface folate-binding protein. Following binding, cell-associated folate-PEG liposomes were internalized by folate-receptor-mediated endocytosis at 37 degrees C but not at 4 degrees C. These folate-PEG liposomes show potential for delivering large quantities of low molecular weight compounds nondestructively into folate receptor-bearing cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8106354

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  115 in total

1.  A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis.

Authors:  Haruya Sato; Yukio Kato; Eiko Hayasi; Tomoyuki Tabata; Manabu Suzuki; Yoshiyuki Takahara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.

Authors:  Ki Young Choi; Gurusamy Saravanakumar; Jae Hyung Park; Kinam Park
Journal:  Colloids Surf B Biointerfaces       Date:  2011-10-20       Impact factor: 5.268

Review 3.  Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives.

Authors:  Ki Young Choi; Gang Liu; Seulki Lee; Xiaoyuan Chen
Journal:  Nanoscale       Date:  2011-12-01       Impact factor: 7.790

4.  In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery.

Authors:  Sumanta K Sahu; Sanjay K Mallick; Susmita Santra; Tapas K Maiti; Sudip K Ghosh; Panchanan Pramanik
Journal:  J Mater Sci Mater Med       Date:  2010-01-29       Impact factor: 3.896

5.  Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form.

Authors:  K E Anderson; L A Eliot; B R Stevenson; J A Rogers
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

6.  Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents.

Authors:  Jonathan F Lovell; Cheng S Jin; Elizabeth Huynh; Honglin Jin; Chulhong Kim; John L Rubinstein; Warren C W Chan; Weiguo Cao; Lihong V Wang; Gang Zheng
Journal:  Nat Mater       Date:  2011-03-20       Impact factor: 43.841

Review 7.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

Review 8.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

9.  Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.

Authors:  Nabil F Saba; Xu Wang; Susan Müller; Mourad Tighiouart; Kwangjae Cho; Shuming Nie; Zhuo Chen; Dong M Shin
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

10.  Targeting tamoxifen to breast cancer xenograft tumours: preclinical efficacy of folate-attached nanoparticles based on alginate-cysteine/disulphide-bond-reduced albumin.

Authors:  A Martínez; E Muñiz; C Teijón; I Iglesias; J M Teijón; M D Blanco
Journal:  Pharm Res       Date:  2013-11-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.